Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

When you're hoarse, sending a voice message, presenting a project at a meeting, dictating an address to your car's navigation system, or simply having a phone call can be difficult."We're a ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Morning nasal congestion can signal allergies, sinusitis, dry air, GERD, or structural nasal issues. ENT experts say that ...

Congestion - that bunged up, stuffy nose ­feeling - is usually a fleeting symptom of a cold which lasts for around a week and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

The National Consumer Disputes Redressal Commission (NCDRC) has directed a Rajasthan-based hospital and its ENT specialist to ...

Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path ...

A Thai woman condemned a private hospital in the central province of Samut Sakhon after treatment for nasal polyps left her boyfriend blind.

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.

GSK’s leadership in respiratory medicine goes beyond science—uniting research, collaboration, and care to transform outcomes ...